[{"from": "human", "value": "Please give me some details about this molecule. [C][C][C][C][=N][C][=Branch2][Branch1][Branch1][=C][Branch2][Ring1][=C][N][Ring1][Branch1][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=C][C][=C][C][=C][Ring1][=Branch1][C][=N][N][N][=N][Ring1][Branch1][C][=Branch1][C][=O][O][C][C][=C][Branch1][=Branch2][O][C][=Branch1][C][=O][O][Ring1][=Branch1][C][C][Branch1][C][C][Branch1][C][C][O]"}, {"from": "gpt", "value": "The molecule is a synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor of angiotensin II in vascular smooth muscle and adrenal gland, thereby competing angiotensin II binding to the receptor. This prevents angiotensin II-induced vasoconstriction and decreases aldosterone production, thereby preventing aldosterone-stimulated sodium retention and potassium excretion."}]